Opparounds

Thursday, August 20, 2026

Opparounds

01
πŸ”¬Psychiatric Research Article

Effects of Brexpiprazole on Functioning in Patients With Schizophrenia Who Have Hostility and Agitation Symptoms: Post Hoc Analysis of Short- and Long-Term Trials

Citrome L, Farovik A, Palma AM, Yildirim M Β· Journal of Clinical Psychiatry Β· July 2026

This post hoc analysis pooled short-term data from three 6-week, randomized, double-blind, placebo-controlled trials of brexpiprazole in acute schizophrenia (n=1,385 analyzed; 692 with baseline hostility per PANSS item P7, 784 with baseline agitation per the PANSS-Excited Component), plus long-term data from two 52-week open-label extensions (n=408). The question was whether brexpiprazole still improves real-world functioning, measured by the Personal and Social Performance (PSP) scale, in patients whose presentation includes hostility or agitation β€” symptoms clinicians sometimes treat as a reason to reach for something more sedating instead.

At Week 6, brexpiprazole (2–4 mg/day) produced significantly greater PSP improvement than placebo in both the hostility subgroup (+2.82 points, P=.014) and the agitation subgroup (+4.05 points, P<.001) β€” the agitation subgroup actually showed the larger effect. Gains continued through the open-label extensions, with functional response rates of 90.6% at Week 58 for the hostility subgroup and 77.5% for the agitation subgroup.

 
πŸ’‘ Why it matters

Baseline hostility or agitation isn't a reason to avoid brexpiprazole in favor of a more sedating agent β€” functional gains held up, and were larger in the agitated subgroup, through more than a year of follow-up.

Read the paper β†’  doi:10.4088/JCP.26m16448

02
πŸ“–Psychotherapy Research Article

Effects of Perceived Working Alliance Quality and Congruence on Naturalistic Psychotherapy Outcome: A Response Surface Analysis

Fanny Alexandra Dietel, Ivo Georgiev, Julia MΓΌller, Tanja Andor, Isabelle Drenckhan, Julienne Seidemann, Heinz Holling, Nexhmedin Morina, Ulrike Buhlmann Β· Psychotherapy Research Β· August 2026

In a naturalistic sample of 353 outpatients receiving CBT and their 95 therapists, both parties rated the working alliance early in treatment. Rather than collapsing patient and therapist ratings into a single discrepancy score β€” which throws away information about whether both raters were high, both low, or split β€” the authors used response surface analysis to model alliance level and patient-therapist congruence as separate predictors of later depression, distress, and quality-of-life outcomes.

Therapist-rated alliance, not patient-rated alliance, predicted better outcomes. Congruence between the two ratings added nothing once alliance level was accounted for β€” there was no penalty for the two parties seeing the relationship differently, only a benefit when the therapist rated it highly. The pattern held after controlling for total session count.

 
πŸ’‘ Why it matters

A therapist's own sense that the alliance is solid may be tracking something clinically real even when the patient's self-report measure doesn't say the same β€” worth weighing as data, not overridden by the WAI score alone.

Read the paper β†’  doi:10.1080/10503307.2025.2553636

03
πŸ’ŠPsychiatric Fact

Gabapentin's dose-response curve bends because its absorption does

Gabapentin isn't absorbed by passive diffusion β€” it crosses the gut wall via the saturable LAT1 amino-acid transporter, the same carrier that moves phenylalanine and leucine. That transporter has a fixed capacity, so as the dose climbs, bioavailability falls: roughly 60% at 900 mg/day but closer to 33% by 3,600 mg/day. Doubling the dose from 1,800 to 3,600 mg does not double serum exposure β€” it adds only a fraction of what the first 1,800 mg contributed.

Pregabalin, by contrast, crosses passively and has linear, dose-proportional kinetics across its range. The clinical implication: if a patient plateaus on high-dose gabapentin for anxiety, neuropathic pain, or alcohol-withdrawal prophylaxis, pushing the dose further is chasing a diminishing return, not correcting an underdose. Splitting the daily dose into more frequent intervals (to reduce the per-dose transporter load) or switching to pregabalin is more likely to move the needle than another increase.

04
πŸ›‹οΈPsychotherapy Teaching Pearl

Irreverence is a calculated destabilization, not sarcasm

DBT names two communication styles a therapist moves between: reciprocal communication β€” warmth, self-disclosure, responsiveness β€” and irreverent communication, which deliberately unbalances the patient by responding in a way they don't expect. Irreverence isn't wit for its own sake. It's reserved for moments when reciprocal warmth would reinforce a maladaptive pattern: a guilt-inducing dropout threat, a rigid catastrophic narrative, a request that's really testing whether the therapist will rescue.

A flat, matter-of-fact, slightly off-script response interrupts the expected sequence and forces the patient to re-engage with what they actually want, rather than the script they're running. It only works from a secure alliance β€” attempted without one, it reads as dismissive rather than disruptive β€” and it is almost always followed immediately by a return to warmth, so the patient experiences a jolt, not a rejection.

 
πŸ—’οΈ Vignette

A patient who skipped homework opens session with, "I guess I'm just a lost cause β€” you should find a real client." The reflex is reassurance, but that reflex has reinforced this exact move for months. Instead: "Well, if you're a lost cause, I've got a waitlist β€” I could open up Tuesdays." Silence. Then genuine curiosity: "But I don't actually think that's true. What's really going on with the homework?"

The deadpan offer breaks the rescue script the patient expects and signals the therapist isn't afraid of the threat, which paradoxically makes it safer to admit the real barrier β€” she'd been avoiding the diary card because the entries would show she'd cut again. The irreverence created the opening; the immediate pivot back to warmth kept the alliance intact.

05
πŸ“°In the News
β€’ The FDA's July 2026 approval of centanafadine (Simtriyo) β€” the first serotonin/norepinephrine/dopamine triple reuptake inhibitor approved for ADHD β€” adds a genuinely new mechanism for patients who've cycled through stimulants and atomoxetine/viloxazine without benefit.  source β†’
β€’ The AASM's April 2026 guideline on combination treatment for chronic insomnia now conditionally recommends starting CBT-I together with medication for some adults, rather than defaulting to CBT-I alone first β€” worth knowing before your next comorbid-insomnia consult.  source β†’